List of Excipients in API centanafadine hydrochloride
Excipients in NDA-approved (novel) drugs containing centanafadine hydrochloride
Detailed excipient profiles for centanafadine hydrochloride
Excipient focus: CELLULOSE, MICROCRYSTALLINE
centanafadine hydrochloride drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Otsuka America Pharmaceutical Inc | centanafadine hydrochloride | 59148-302 |
| >Company | >Ingredient | >NDC |
centanafadine hydrochloride drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER
centanafadine hydrochloride drug variants containing ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER
| Company | Ingredient | NDC |
|---|---|---|
| Otsuka America Pharmaceutical Inc | centanafadine hydrochloride | 59148-302 |
| >Company | >Ingredient | >NDC |
centanafadine hydrochloride drug variants not containing ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C YELLOW NO. 6
centanafadine hydrochloride drug variants containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| Otsuka America Pharmaceutical Inc | centanafadine hydrochloride | 59148-302 |
| >Company | >Ingredient | >NDC |
centanafadine hydrochloride drug variants not containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
centanafadine hydrochloride drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Otsuka America Pharmaceutical Inc | centanafadine hydrochloride | 59148-302 |
| >Company | >Ingredient | >NDC |
centanafadine hydrochloride drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
centanafadine hydrochloride drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Otsuka America Pharmaceutical Inc | centanafadine hydrochloride | 59148-302 |
| >Company | >Ingredient | >NDC |
centanafadine hydrochloride drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PLASACRYL T20
centanafadine hydrochloride drug variants containing PLASACRYL T20
| Company | Ingredient | NDC |
|---|---|---|
| Otsuka America Pharmaceutical Inc | centanafadine hydrochloride | 59148-302 |
| >Company | >Ingredient | >NDC |
centanafadine hydrochloride drug variants not containing PLASACRYL T20
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLY(METHYL ACRYLATE-CO-METHYL METHACRYLATE-CO-METHACRYLIC ACID 7:3:1; 280000 MW)
centanafadine hydrochloride drug variants containing POLY(METHYL ACRYLATE-CO-METHYL METHACRYLATE-CO-METHACRYLIC ACID 7:3:1; 280000 MW)
| Company | Ingredient | NDC |
|---|---|---|
| Otsuka America Pharmaceutical Inc | centanafadine hydrochloride | 59148-302 |
| >Company | >Ingredient | >NDC |
centanafadine hydrochloride drug variants not containing POLY(METHYL ACRYLATE-CO-METHYL METHACRYLATE-CO-METHACRYLIC ACID 7:3:1; 280000 MW)
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 80
centanafadine hydrochloride drug variants containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| Otsuka America Pharmaceutical Inc | centanafadine hydrochloride | 59148-302 |
| >Company | >Ingredient | >NDC |
centanafadine hydrochloride drug variants not containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
centanafadine hydrochloride drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Otsuka America Pharmaceutical Inc | centanafadine hydrochloride | 59148-302 |
| >Company | >Ingredient | >NDC |
centanafadine hydrochloride drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
centanafadine hydrochloride drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Otsuka America Pharmaceutical Inc | centanafadine hydrochloride | 59148-302 |
| >Company | >Ingredient | >NDC |
centanafadine hydrochloride drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
centanafadine hydrochloride drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Otsuka America Pharmaceutical Inc | centanafadine hydrochloride | 59148-302 |
| >Company | >Ingredient | >NDC |
centanafadine hydrochloride drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
centanafadine hydrochloride drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Otsuka America Pharmaceutical Inc | centanafadine hydrochloride | 59148-302 |
| >Company | >Ingredient | >NDC |
centanafadine hydrochloride drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch